HomeHome E-mail this pageE-mail this page Print this pagePrint this page
<img border="0" src="images/04subleft.gif" width="474" height="88" alt="The Mark of Individualized Medicine"> monogram biosciences
About Us HIV Products Oncology Products Pharma Partnerships Investors/Media Careers
Products and Services
Archived Webcasts
Contact Us


Products and Services
Novel Drug Testing Services

PhenoScreen™

PhenoSense™ for Entry Inhibitor Susceptibility Assay

Trofile™ – Monogram’s Co-receptor Tropism Assay

GeneSeq™ for Entry Inhibitors (HIV Envelope Sequencing) Assay

PhenoSense™ and GeneSeq™ for Integrase Inhibitors Assays

PhenoSense GT™ for Reverse Transcriptase and Protease Inhibitors Assay

PhenoSense™ HIV for Reverse Transcriptase and Protease Inhibitors Assay

GeneSeq™ HIV for Reverse Transcriptase and Protease Inhibitors Assay

Clonal Analysis

HCV

PhenoSense™ HIV Neutralization Assay and Vaccine Development

Database Queries

Preparing your IND/NDA

VLink online reporting system


Archived Webcasts
Archived Webcast: Effective Implementation of Resistance Testing for Screening Patients and for Optimizing Background in HIV Clinical Trials

Archived Webcast: Monogram Biosciences’ Entry and Tropsim Assays

Archived Webcast: HIV/SIV Antibody Neutralization Assay


Contact Us
Information Request

Register for Updates
Pharma Partnerships

Type size: + -
PhenoSense™ for Entry Inhibitor Susceptibility Assay

As a new drug class, entry inhibitors are a promising breakthrough that will offer an effective treatment option to patients with a high level of treatment experience and resistance to currently available drugs. The successful development of new drugs in the entry inhibitor class requires unique drug resistance assay technology to assess the susceptibility of HIV, particularly multi-drug resistant HIV, to these new agents.

Monogram has applied its PhenoSense technology to develop a phenotypic assay for the evaluation of entry inhibitor drug susceptibility. The assay has been widely used in clinical trials, including the Phase III studies of enfuvirtide (Fuzeon) and viral susceptibility to enfuvirtide is commercially available in Monogram's CLIA certified laboratory to help guide patient therapy. PhenoSense HIV Entry is complemented by Monogram's envelope sequencing technology, GeneSeq HIV Entry.

Click here to download slide presentation featuring vector and transfections schematics.

Reference: Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G. & Perros, M.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol in press (2007).

For more information on Monogram assays, services and pricing, please contact us.

Contact Us  |  Site Map  |  Privacy Policy  |  Health Disclaimer  |  HIPAA Practice  | Home